# Open-Label Natalizumab Safety Extension Study

> **NCT00276172** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 1615 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Natalizumab

## Key facts

- **NCT ID:** NCT00276172
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2005-10
- **Final completion:** 2006-01
- **Target enrollment:** 1615 (ACTUAL)
- **Last updated:** 2009-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276172, "Open-Label Natalizumab Safety Extension Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00276172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*